BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25972343)

  • 1. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
    Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
    Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
    Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
    Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.
    Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X
    PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
    Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
    Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia.
    Bahari G; Hashemi M; Naderi M; Taheri M
    Asian Pac J Cancer Prev; 2016; 17(8):3959-62. PubMed ID: 27644645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.
    Asmar F; Punj V; Christensen J; Pedersen MT; Pedersen A; Nielsen AB; Hother C; Ralfkiaer U; Brown P; Ralfkiaer E; Helin K; Grønbæk K
    Haematologica; 2013 Dec; 98(12):1912-20. PubMed ID: 23831920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
    Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.
    Palomo L; Malinverni R; Cabezón M; Xicoy B; Arnan M; Coll R; Pomares H; García O; Fuster-Tormo F; Grau J; Feliu E; Solé F; Buschbeck M; Zamora L
    Epigenetics; 2018; 13(1):8-18. PubMed ID: 29160764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
    Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
    Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.
    Yamazaki J; Taby R; Jelinek J; Raynal NJ; Cesaroni M; Pierce SA; Kornblau SM; Bueso-Ramos CE; Ravandi F; Kantarjian HM; Issa JP
    J Natl Cancer Inst; 2015 Nov; 108(2):. PubMed ID: 26568194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX.
    Ko M; An J; Bandukwala HS; Chavez L; Aijö T; Pastor WA; Segal MF; Li H; Koh KP; Lähdesmäki H; Hogan PG; Aravind L; Rao A
    Nature; 2013 May; 497(7447):122-6. PubMed ID: 23563267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
    Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
    Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes in DNA methylation patterns in canine lymphoma cell lines demonstrated by genome-wide quantitative DNA methylation analysis.
    Yamazaki J; Jelinek J; Hisamoto S; Tsukamoto A; Inaba M
    Vet J; 2018 Jan; 231():48-54. PubMed ID: 29429487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis.
    Tulstrup M; Soerensen M; Hansen JW; Gillberg L; Needhamsen M; Kaastrup K; Helin K; Christensen K; Weischenfeldt J; Grønbæk K
    Nat Commun; 2021 Oct; 12(1):6061. PubMed ID: 34663818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.